{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T23:22:53Z","timestamp":1751930573411},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.plefa.2012.09.004","type":"journal-article","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T21:31:22Z","timestamp":1349991082000},"page":"185-188","source":"Crossref","is-referenced-by-count":9,"title":["No effect of high-dose atorvastatin on leukotriene B4 formation from neutrophils in patients treated with coronary bypass surgery:"],"prefix":"10.1016","volume":"87","author":[{"given":"C.","family":"Lysgaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.H.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lundbye-Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Riahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.B.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.plefa.2012.09.004_bib1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.plefa.2012.09.004_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10557-008-6140-9","article-title":"Leukotriene signaling in atherosclerosis and ischemia","volume":"23","author":"Back","year":"2009","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.plefa.2012.09.004_bib3","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1073\/pnas.0602414103","article-title":"Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability","volume":"103","author":"Qiu","year":"2006","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.plefa.2012.09.004_bib4","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1161\/01.ATV.0000172632.96987.2d","article-title":"Association between 5-lipoxygenase expression and plaque instability in humans","volume":"25","author":"Cipollone","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.plefa.2012.09.004_bib5","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1073\/pnas.242716099","article-title":"Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis","volume":"100","author":"Spanbroek","year":"2003","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.plefa.2012.09.004_bib6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1161\/01.RES.0000028008.99774.7F","article-title":"Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice","volume":"91","author":"Mehrabian","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.plefa.2012.09.004_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng1692","article-title":"A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction","volume":"38","author":"Helgadottir","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.plefa.2012.09.004_bib8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1086\/428066","article-title":"Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population","volume":"76","author":"Helgadottir","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.plefa.2012.09.004_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ng1311","article-title":"The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke","volume":"36","author":"Helgadottir","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.plefa.2012.09.004_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00439-008-0619-0","article-title":"Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis","volume":"125","author":"Crosslin","year":"2009","journal-title":"Hum. Genet."},{"key":"10.1016\/j.plefa.2012.09.004_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa025079","article-title":"Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis","volume":"350","author":"Dwyer","year":"2004","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.plefa.2012.09.004_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","article-title":"Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis","volume":"115","author":"Lorenz","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.plefa.2012.09.004_bib13","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","article-title":"Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients","volume":"52","author":"Mills","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.plefa.2012.09.004_bib14","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.plefa.2012.09.004_bib15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","article-title":"Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease","volume":"104","author":"Faergeman","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.plefa.2012.09.004_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11883-009-0085-8","article-title":"Statin effects on both low-density lipoproteins and high-density lipoproteins: is there a dual benefit?","volume":"12","author":"Uno","year":"2010","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.plefa.2012.09.004_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1538574410362922","article-title":"Basic science review: statin therapy\u2014Part I: The pleiotropic effects of statins in cardiovascular disease","volume":"44","author":"Sadowitz","year":"2010","journal-title":"Vasc. Endovasc. Surg."},{"key":"10.1016\/j.plefa.2012.09.004_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(03)00239-9","article-title":"Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities","volume":"173","author":"Rosenson","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plefa.2012.09.004_bib19","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","article-title":"Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50mg\/dl with rosuvastatin. The JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"57","author":"Hsia","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.plefa.2012.09.004_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000296017","article-title":"Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway","volume":"115","author":"Zhou","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.plefa.2012.09.004_bib21","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1161\/01.ATV.17.8.1521","article-title":"Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats","volume":"17","author":"Kimura","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.plefa.2012.09.004_bib22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.metabol.2005.03.021","article-title":"Angiotensin II-induced oxidative burst is fluvastatin sensitive in neutrophils of patients with hypercholesterolemia","volume":"54","author":"Seres","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.plefa.2012.09.004_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.amjcard.2008.02.090","article-title":"Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome","volume":"102","author":"Gomez-Hernandez","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.plefa.2012.09.004_bib24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijcard.2005.08.032","article-title":"The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery","volume":"111","author":"Riahi","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.plefa.2012.09.004_bib25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00439-008-0489-5","article-title":"Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease","volume":"123","author":"Assimes","year":"2008","journal-title":"Hum. Genet."},{"key":"10.1016\/j.plefa.2012.09.004_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1042\/CS20060271","article-title":"Leukotriene B4 production in healthy subjects carrying variants of the arachidonate 5-lipoxygenase-activating protein gene associated with a risk of myocardial infarction","volume":"112","author":"Maznyczka","year":"2007","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.plefa.2012.09.004_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1744-313X.2007.00671.x","article-title":"A functional Sp1\/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene is not associated with myocardial infarction","volume":"34","author":"Gonzalez","year":"2007","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/j.plefa.2012.09.004_bib28","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.4049\/jimmunol.181.5.3515","article-title":"Phosphorylation of 5-lipoxygenase at ser523 by protein kinase a determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production","volume":"181","author":"Ye","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.plefa.2012.09.004_bib29","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1161\/01.ATV.0000110503.16605.15","article-title":"Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms","volume":"24","author":"Subbarao","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.plefa.2012.09.004_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/286264a0","article-title":"A potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes","volume":"286","author":"Ford-Hutchinson","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.plefa.2012.09.004_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.plefa.2012.04.011","article-title":"Insertion-deletions in a FADS2 intron 1 conserved regulatory locus control expression of fatty acid desaturases 1 and 2 and modulate response to simvastatin","volume":"87","author":"Reardon","year":"2012","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"}],"container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327812001548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327812001548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T01:51:33Z","timestamp":1542678693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952327812001548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0952327812001548"],"URL":"https:\/\/doi.org\/10.1016\/j.plefa.2012.09.004","relation":{},"ISSN":["0952-3278"],"issn-type":[{"value":"0952-3278","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}